Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Tarsus Pharmaceuticals (TARS) Accumulated Depreciation & Amortization (2020 - 2025)

Tarsus Pharmaceuticals (TARS) has 6 years of Accumulated Depreciation & Amortization data on record, last reported at $1.8 million in Q4 2025.

  • For Q4 2025, Accumulated Depreciation & Amortization rose 48.24% year-over-year to $1.8 million; the TTM value through Dec 2025 reached $1.8 million, up 48.24%, while the annual FY2025 figure was $1.8 million, 48.24% up from the prior year.
  • Accumulated Depreciation & Amortization reached $1.8 million in Q4 2025 per TARS's latest filing, up from $1.4 million in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $1.8 million in Q4 2025 and bottomed at $142000.0 in Q1 2021.
  • Average Accumulated Depreciation & Amortization over 5 years is $659250.0, with a median of $393000.0 recorded in 2022.
  • Peak YoY movement for Accumulated Depreciation & Amortization: tumbled 72.74% in 2024, then soared 383.45% in 2025.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $221000.0 in 2021, then surged by 47.51% to $326000.0 in 2022, then surged by 169.02% to $877000.0 in 2023, then skyrocketed by 39.68% to $1.2 million in 2024, then skyrocketed by 48.24% to $1.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Depreciation & Amortization were $1.8 million in Q4 2025, $1.4 million in Q3 2025, and $913000.0 in Q2 2025.